LuciAbe — Abemaciclib 50 mg, 28 pcs, Lucius

LuciAbe — Abemaciclib Tablets 50 mg, 28 Tablets

Product code: 501

8046₴ 8761₴ -8% On order · from 10 days

Analogues

Abemaxen 150 LuciAbe
1
Active ingredient
Dosage form Tablets
Tablets per pack 28

LuciAbe is an advanced targeted antineoplastic agent belonging to the cyclin-dependent kinase (CDK4 and CDK6) inhibitor class, indicated for the treatment of hormone-dependent breast cancers. The active pharmaceutical ingredient is abemaciclib at a strength of 50 mg supplied as film-coated oral tablets (Abemaciclib Tablets 50 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Abemaciclib is a selective inhibitor of CDK4 and CDK6 kinases, which play a pivotal role in regulating cell cycle progression from the G1 phase to the DNA synthesis phase (S-phase). Blocking these enzymes prevents retinoblastoma protein (Rb) phosphorylation, halting the cell cycle and inducing growth arrest or apoptosis in tumor cells. Abemaciclib is administered either in combination with endocrine therapy (aromatase inhibitors or fulvestrant) or as monotherapy in patients with HR-positive, HER2-negative advanced or metastatic breast cancer.

Supplied in a package containing 28 tablets of 50 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciAbe 50 mg:

  • ✅ Selective Action (CDK4/6 Inhibitor): Potent and selective suppression of tumor cell cycle progression.
  • ✅ Dosing Flexibility: The 50 mg strength allows precise dose titration when managing adverse events.
  • ✅ Proven Efficacy: Significant prolongation of progression-free survival in combination with hormone therapy.
  • ✅ Convenient Oral Administration: Taken orally twice daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Verzenio).

LuciAbe is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Abemaciclib — 50 mg.
  • Excipients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate. Coating: hypromellose, titanium dioxide, macrogol, talc, colorants.

Packaging and Presentation: Film-coated tablets, 50 mg strength. Each package contains 28 tablets along with prescribing information. Labeled with LuciAbe (Abemaciclib Tablets 50 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Abemaciclib is a potent, selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Continuous exposure to abemaciclib inhibits retinoblastoma protein (Rb) phosphorylation, halting the cell cycle in the G1 phase and preventing transition to the DNA synthesis phase, thereby suppressing tumor cell proliferation. In breast cancer models, sustained CDK4 and CDK6 inhibition leads to irreversible cellular senescence.

Pharmacokinetics:

  • Absorption: Following oral ingestion, abemaciclib absorption is slow; peak plasma concentration (Tmax) is achieved within approximately 6 hours. Absolute bioavailability is approximately 45%. Food intake does not have a clinically relevant effect on absorption parameters.
  • Distribution: Human plasma protein binding is approximately 963% to 96%. High volume of distribution indicates extensive tissue penetration.
  • Metabolism: Extensively metabolized in the liver predominantly via CYP3A4 to form major active metabolites (M2 and M20).
  • Elimination: Excreted predominantly via feces (approx. 81% as metabolites and unchanged drug) and renally (approx. 3%). Terminal elimination half-life (T1/2) averages approximately 24 hours.

LuciAbe is indicated in adult patients for:

  • Breast Cancer: Treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in disease progression following endocrine therapy, as well as adjuvant treatment in early-stage high-risk disease.

LuciAbe is administered orally twice daily every day (approximately every 12 hours).

Dosing Regimen:
The recommended standard dose in combination with endocrine therapy is 150 mg (three 50 mg tablets or one 150 mg tablet) twice daily. As monotherapy, the recommended dose is also 150 mg twice daily. The 50 mg strength facilitates convenient dose titration (reduction to 100 mg or 50 mg twice daily) when managing adverse reactions.

Administration Guidelines:
Tablets should be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses).

Administration of LuciAbe is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to abemaciclib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Abemaciclib is metabolized primarily in the liver via CYP3A4:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly increase abemaciclib plasma concentrations. Avoid concurrent use or adjust dosage accordingly.
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Decrease abemaciclib blood concentrations and reduce efficacy. Avoid concurrent use.
  • Transporter Substrates (e.g., metformin): Abemaciclib may inhibit renal transporters, requiring blood glucose monitoring or dose adjustments for co-administered drugs.

Pregnancy:
LuciAbe is contraindicated during pregnancy. Based on its mechanism of action, abemaciclib may cause fetal harm when administered to pregnant women. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 3 weeks following the final dose.

Lactation:
Excretion of abemaciclib into human breast milk cannot be ruled out. Breastfeeding must be discontinued during treatment and for at least 3 weeks post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract (Very Common): Diarrhea (primary adverse effect requiring prompt antidiarrheal therapy and hydration), nausea, vomiting, abdominal pain, decreased appetite.
  • Hematologic Toxicity: Neutropenia, leukopenia, anemia, thrombocytopenia. Routine complete blood count monitoring required.
  • Hepatic Abnormalities: Elevations in liver transaminases (ALT, AST), bilirubin. Liver function monitoring required.
  • General Disorders: Fatigue, asthenia, infections, alopecia, venous thromboembolism.

Symptoms:
Specific acute overdose symptoms of abemaciclib are unestablished. Anticipated manifestations include exacerbated adverse reactions (diarrhea, fatigue, hematologic toxicity).

Treatment:
No specific antidote exists. Supportive and symptomatic care should be initiated under strict medical supervision in case of overdose.

Storage Requirements for LuciAbe 50 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciAbe 50 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Abemaciclib Tablets 50 mg, and 28 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00